The effect of alendronate doped calcium phosphates on bone cells activity

Bone

Volumn 51, Issue 5, 2012, Pages 944-952

  Boanini, Elisa ^a   Torricelli, Paola ^b   Gazzano, Massimo ^c   Fini, Milena ^b   Bigi, Adriana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c CNR   (Italy)

Author keywords

Bisphosphonate; Co culture; Octacalcium phosphate; Osteoblast; Osteoclast

Indexed keywords

ALENDRONIC ACID; CALCIUM PHOSPHATE; HYDROXYAPATITE;

ADULT; ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; SURFACE PROPERTY; X RAY DIFFRACTION;

ALENDRONATE; CALCIUM PHOSPHATES; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DIPHOSPHONATES; DURAPATITE; HUMANS; MICROSCOPY, ELECTRON, SCANNING; OSTEOBLASTS; OSTEOCLASTS; X-RAY DIFFRACTION;

EID: 84867074995     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.07.020     Document Type: Article

References (64)

1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80-100.
2. Russell R.G.G. Bisphosphonates: the first 40years. Bone 2011, 49:2-19.
3. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
4. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
5. Russell R.G.G. Determinants of structure-function relationships among bisphosphonates. Bone 2007, 40:S21-S25.
6. Russell R.G.G., Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106.
7. Compston J.E. The therapeutic use of bisphosphonates. Br Med J 1994, 309:711-715.
8. Martin T.J., Grill V. Bisphosphonates-mechanisms of action. Aust Prescr 2000, 23:130-132.
9. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
10. Green J.R. Bisphosphonates: preclinical review. Oncologist 2004, 9:3-13.
11. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
12. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
13. Ott S.M. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005, 90:1897-1899.
14. Favia G., Pilolli G.P., Maiorano E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosisof the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 2009, 45:406-413.
15. Pazianas M., Abrahamsen B. Safety of bisphosphonates. Bone 2011, 49:103-110.
16. Josse S., Faucheux C., Soueidan A., Grimandi G., Massiot D., Alonso B., et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005, 26:2073-2080.
17. Roussiere H., Montavon G., Laib S., Janvier P., Alonso B., Fayon F., et al. Hybrid materials applied to biotechnologies: coating of calcium phosphates for the design of implants active against bone resorption disorders. J Mater Chem 2005, 15:3869-3875.
18. Roussiere H., Fayon F., Alonso B., Rouillon T., Schnitzler V., Verron E., et al. Reaction of zoledronate with beta-tricalcium phosphate, for the design of potential drug device combined systems. Chem Mater 2008, 20:182-191.
19. Schnitzler V., Fayon F., Despas C., Khairoun I., Mellier C., Rouillon T., et al. Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: critical influence of the drug introduction mode on the in vitro cement properties. Acta Biomater 2011, 7:759-770.
20. Panzavolta S., Torricelli P., Bracci B., Fini M., Bigi A. Alendronate and pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem 2009, 103:101-106.
21. Panzavolta S., Torricelli P., Bracci B., Fini M., Bigi A. Functionalization of biomimetic calcium phosphate bone cements with alendronate. J Inorg Biochem 2010, 104:1099-1106.
22. Peter B., Pioletti D.P., Laïb S., Bujoli B., Pilet P., Janvier P., et al. Calcium phosphate drug delivery system: influence of local Zoledronate release on bone implant osteointegration. Bone 2005, 36:52-60.
23. Seshima H., Yoshinari M., Takemoto S., Hattori M., Kawada E., Inoue T., et al. Control of bisphosphonate release using hydroxyapatite granules. J Biomed Mater Res B Appl Biomater 2006, 78B:215-221.
24. Boanini E., Gazzano M., Rubini K., Bigi A. Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure. Adv Mater 2007, 19:2499-2502.
25. Boanini E., Torricelli P., Gazzano M., Giardino R., Bigi A. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 2008, 29:790-796.
26. Bigi A., Boanini E., Capuccini C., Fini M., Mihailescu I.N., Ristoscu C., et al. Biofunctional alendronate-hydroxyapatite thin films deposited by matrix assisted pulsed laser evaporation. Biomaterials 2009, 30:6168-6177.
27. Verron E., Gauthier O., Janvier P., Pilet P., Lesoeur J., Bujoli B., et al. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite. Biomaterials 2010, 31:7776-7784.
28. Boanini E., Torricelli P., Gazzano M., Fini M., Bigi A. The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells in vitro. Biomaterials 2012, 33:722-730.
29. Boanini E., Gazzano M., Bigi A. Time course of zoledronate interaction with hydroxyapatite nanocrystals. J Phys Chem C 2012, 116:15812-15818.
30. Qi M., Hu J., Li J., Li J., Dong W., Feng X., et al. Effect of zoledronate acid treatment on osseointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbit. Bone 2012, 50:119-127.
31. Brown W.E., Smith J.P., Lehr J.R., Frazier A.W. Octacalcium phosphate and hydroxyapatite: crystallographic and chemical relations between octacalcium phosphate and hydroxyapatite. Nature 1962, 196:1050-1055.
32. 2O. J Crystallogr Spectrosc Res 1988, 18:235-250.
33. Boanini E., Gazzano M., Rubini K., Bigi A. Collapsed octacalcium phosphate stabilized by ionic substitutions. Cryst Growth Des 2010, 10:3612-3617.
34. Barinov S.M., Komlev V.S. Osteoinductive ceramic materials for bone tissue restoration: octacalcium phosphate (review). Inorg Mater Appl Res 2010, 1:175-181.
35. Suzuki O., Kamakura S., Katagiri T. Surface chemistry and biological responses to synthetic octacalcium phosphate. J Biomed Mater Res B Appl Biomater 2006, 77B:201-212.
36. Murakami Y., Honda Y., Anada T., Shimauchi H., Suzuki O. Comparative study on bone regeneration by synthetic octacalcium phosphate with various granule sizes. Acta Biomater 2010, 6:1542-1548.
37. Kamakura S., Sasaki K., Homma T., Honda Y., Anada T., Echigo S., et al. The primacy of octacalcium phosphate collagen composites in bone regeneration. J Biomed Mater Res A 2007, 83A:725-733.
38. Suzuki O., Kamakura S., Katagiri T., Nakamura M., Zhao B., Honda Y., et al. Bone formation enhanced by implanted octacalcium phosphate involving conversion into Ca-deficient hydroxyapatite. Biomaterials 2006, 27:2671-2681.
39. Suzuki O. Octacalcium phosphate: osteoconductivity and crystal chemistry. Acta Biomater 2010, 6:3379-3387.
40. Kuljanin J., Janković I., Nedeljković J., Prstojević D., Marinković V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. J Pharm Biomed Anal 2002, 28:1215-1220.
41. Bigi A., Bracci B., Cuisinier F., Elkaim R., Fini M., Mayer I., et al. Human osteoblast response to pulsed laser deposited calcium phosphate coatings. Biomaterials 2005, 26:2381-2389.
42. Habibovic P., Yuan H., van der Valk C.M., Meijer G., van Blitterswijk C.A., de Groot K. 3D microenvironment as essential element for osteoinduction by biomaterials. Biomaterials 2005, 26:3565-3575.
43. Yang X., Gao X., Gan Y., Gao C., Zhang X., Ting K., et al. Facile synthesis of octacalcium phosphate nanobelts: growth mechanism and surface adsorption properties. J Phys Chem C 2010, 114:6265-6271.
44. Juillard A., Falgayrac G., Cortet B., Vieillard M.H., Azaroual N., Hornez J.C., et al. Molecular interactions between zoledronic acid and bone: an in vitro Raman microspectroscopic study. Bone 2010, 47:895-904.
45. Fowler B.O., Marković M., Brown W.E. Octacalcium phosphate. 3. Infrared and raman vibrational spectra. Chem Mater 1993, 5:1417-1423.
46. Zhou H., Lawrence J.G., Touny A.H., Bhaduri S.B. Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V. J Mater Sci Mater Med 2012, 23:365-374.
47. Sun J., Song F., Zhang W., Sexton B.E., Windsor L.J. Effects of alendronate on human osteoblast-like MG63 cells and matrix metalloproteinases. Arch Oral Biol 2012, 57:728-736.
48. Bernhardt A., Thieme S., Domaschke H., Springer A., Rösen-Wolff A., Gelinsky M. Crosstalk of osteoblast and osteoclast precursors on mineralized collagen-towards an in vitro model for bone remodeling. J Biomed Mater Res A 2010, 95:848-856.
49. Heinemann C., Heinemann S., Worch H., Hanke T. Development of an osteoblast/osteoclast co-culture derived by human bone marrow stromal cells and human monocytes for biomaterials testing. Eur Cell Mater 2011, 21:80-93.
50. Hashiguchi D., Fukushima H., Nakamura M., Morikawa K., Yasuda H., Udagawa N., et al. Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. J Dent Res 2011, 90:912-917.
51. Zhu M., Zhang P., Zhang X., Lu B., Dai C.L., Li Y.M., et al. Impact of osteoclast-like cells cultured on bone wafer and their sub-cellular structures on osteoblast. Zhonghua Yi Xue Za Zhi 2005, 23:738-742.
52. Galvin R.J., Cullison J.W., Avioli L.V., Osdoby P.A. Influence of osteoclasts and osteoclast-like cells on osteoblast alkaline phosphatase activity and collagen synthesis. J Bone Miner Res 1994, 9:1167-1178.
53. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurukai T., Itoh K., et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone 1999, 25:517-523.
54. Deyama Y., Takeyama S., Koshikawa M., Shirai Y., Yoshimura Y., Nishikata M., et al. Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells. Biochem Biophys Res Commun 2000, 274:249-254.
55. Anada T., Kumagai T., Honda Y., Masuda T., Kamijo R., Kamakura S., et al. Dose-dependent opsteogenic effect of octacalcium phosphate on mouse bone marrow stromal cells. Tissue Eng 2008, 14:965-978.
56. Wittrant Y., Couillaud S., Theoleyre S., Dunstan C., Heymann D., Rédini F. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun 2002, 293:38-44.
57. Ohe J.Y., Kwon Y.D., Lee H.W. Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clin Oral Investig 2012, 16:1153-1159.
58. Koch F.P., Merkel C., Ziebart T., Smeets R., Walter C., Al-Nawas B. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig 2012, 16:79-86.
59. Moon H.J., Yun Y.P., Han C.W., Kim M.S., Kim S.E., Bae M.S., et al. Effect of heparin and alendronate coating on titanium surfaces on inhibition of osteoclast and enhancement of osteoblast function. Biochem Biophys Res Commun 2011, 413:194-200.
60. Takami M., Mochizuki A., Yamada A., Tachi K., Zhao B., Miyamoto Y., et al. Osteoclast differentiation induced by synthetic octacalcium phosphate through rankl expression in osteoblasts. Tissue Eng Part A 2009, 15:3991-4000.
61. Hemingway F., Cheng X., Knowles H.J., Estrada F.M., Gordon S., Athanasou N.A. In vitro generation of mature human osteoclasts. Calcif Tissue Int 2011, 89:389-395.
62. Troen B.R. The regulation of cathepsin K gene expression. Ann N Y Acad Sci 2006, 1068:165-172.
63. Benford H.L., McGowan N.W., Helfrich M.H., Nuttall M.E., Rogers M.J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001, 28:465-473.
64. Tanuma Y., Anada T., Honda Y., Kawai T., Kamakura S., Echigo S., et al. Granule size-dependent bone regenerative capacity of octacalcium phosphate in collagen matrix. Tissue Eng 2012, 18:546-557.